World Journal of
Pharmaceutical and Life Sciences

TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF ROSUVASTATIN, SIMVASTATIN AND ATORVASTATIN IN NEWLY DIAGNOSED TYPE 2 DIABETIC PATIENTS WITH DYSLIPIDEMIA

Dr. Shaikh Alimuddin, Dr. Farahanaz Irani B.,* and Dr. Deepak. S.Bhosle

ABSTRACT

Introduction: Diabetes mellitus is an metabolic disorder characterized by hyperglycemia and altered metabolism of lipid, protein and carbohydrate metabolism. Method: A total of 60 diagnosed cases of patients of Type II Diabetes Mellitus well controlled on oral hypoglycemic drugs in age group of 30-65 years who have satisfied inclusion and exclusion criteria and have consented to participate in study were enrolled. Each enrolled subjects Type 2 Diabetes Mellitus patients well controlled on oral hypoglycemic drugs. All patients had fasting samples of blood sent for evaluation of lipid profile. They were randomly allocated into 3 groups of 20 each. Group I received Atrovastatin 10 mg O.D. Group II Simvastatin 10 mg O.D. Group III Rosuvastain 10 mg O.D. for 3 months. Result: The results of our study are comparable to the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). JUPITER Trial provides yet more evidence about the effectiveness of statin therapy in reducing cardiovascular risk, even among persons who would not currently be considered for pharmacotherapy.

[Full Text Article]   [Download Certificate]